Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases

Abstract Background Despite the reported efficacy of osimertinib, central nervous system (CNS) progression is still frequent in EGFR-mutated NSCLC. This study aimed to reveal site-specific resistant mechanisms to osimertinib and investigate subsequent treatments for leptomeningeal metastases (LM). M...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Mei-Mei Zheng, Yang-Si Li, Hai-Yan Tu, Hao Sun, Kai Yin, Ben-Yuan Jiang, Jin-Ji Yang, Xu-Chao Zhang, Qing Zhou, Chong-Rui Xu, Zhen Wang, Hua-Jun Chen, De-Xiang Zhou, Yi-Long Wu
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-05-01
coleção:	BMC Medicine
Assuntos:	Cerebrospinal fluid Leptomeningeal metastases Osimertinib
Acesso em linha:	https://doi.org/10.1186/s12916-022-02387-0
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!